Transparency and Health Technology Assessment cooperation as proposed by the Regulation are the only real antidote to secrecy and political games Why EURORDIS supports the proposal for a Regulation on Health Technology Assessment (HTA) Cooperation in Europe 30 March 2018, Paris – EURORDIS-Rare Diseases Europe, an alliance of 798 rare disease patient organisations from 69 countries, calls on the European Parliament…
EU consultation · In Force
EU cooperation on Health Technology Assessment
7 submissions from 7 organizations told the European Commission what they think about this file. Here is what each of them said, in their own words.
Who showed up
4 submissions from industry (companies and their trade associations) against 3 from civil society: NGOs, consumer organizations, environmental groups and trade unions.
Industry 4Civil society 3Public authorities, academia, other 0
Groupings use the respondent type each organization selected when filing. Counting submissions, not organizations: a body that filed twice is counted twice.
The file, right now
The consultation closed on 2 Apr 2018; it ran from 1 Feb 2018.
- Policy area
- Health & food (DG SANTE)
- Where it stands
- Awaiting adoption
- Legislative stage
- In Force
- Commission reference
- COM(2018)51
How it got here
- Proposal for a regulation2 Apr 2018
Showing 7 of 7 submissions.
EFPIA welcomes the Commission’s proposal for a Regulation on HTA. This proposal presents a unique opportunity to ensure a degree of harmonisation throughout the European Union, thereby leading to faster patient access to new innovative medicines and synergies in clinical evidence generation needs and assessment by Member States.
COCIR welcomes the EC proposal on HTA cooperation in the European Union, adopted on 31 January 2018, in which the majority of the concerns highlighted in COCIR contribution to the European Commission public consultation on strengthening of the EU cooperation on HTA are considered.
JJ
Johnson & Johnson
· · filed 29 Mar 2018 · source
Johnson & Johnson (JnJ) welcomes the opportunity to comment on the proposed HTA Regulation. Our companies provide innovative technologies across the Pharmaceutical, Medical Device and Diagnostic sectors, advancing the health and well-being of people around the world. A significant proportion of our technologies are therefore in scope of the Regulation.
BEUC comments to European Commission’s proposal Regulation Health Technology Assessment The European Consumers Organization (BEUC) welcomes the European Commission’s proposal on Health Technology Assessment (HTA). Too many new drugs or medical devices do not make a real difference compared to those already on the market but are nonetheless reimbursed by healthcare systems.
Pharmaceutical manufacturers can benefit from a single European HTA process, as the different national and regional requirements pose major challenges for companies. The starting point and duration of the HTA process and clinical requirements within the EU Member States vary.
Filed in German · English published by the European Commission
GM
Global Medic Force Foundation
· · filed 12 Feb 2018 · source
Concerning the proposal for a regulation of the European Parliament and of the Council on EU health technology assessment (HTA) and amending Directive 2011/24/EU, Global Medic Force sees this as a very necessary step to address the current qualitative and quantitive inequalities evinced in healthcare availability, diagnostic, prevention and delivery inequities within member states.
Take the dataCSV: all 7 submissionsJSONFull text, not the excerpt. Free to cite.Search every submission →
Method. Every quote is verbatim from the organization’s own submission to the European Commission, trimmed to its opening passage and never summarized by a model. Where a submission was filed in another EU language we show the English text the European Commission publishes alongside it, labeled on the quote; the original is one click away at the source. Groupings use the respondent type the organization itself selected when filing. We deliberately do not label anyone “supportive” or “opposed”. You read what they wrote and draw your own conclusion. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.